company background image
A322970 logo

Moogene Medi XKON:A322970 Stock Report

Last Price

₩2.58k

Market Cap

₩25.8b

7D

4.5%

1Y

-25.9%

Updated

23 Mar, 2024

Data

Company Financials

Moogene Medi Co., Ltd.

XKON:A322970 Stock Report

Market Cap: ₩25.8b

A322970 Stock Overview

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology.

A322970 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Moogene Medi Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Moogene Medi
Historical stock prices
Current Share Price₩2,580.00
52 Week High₩4,015.00
52 Week Low₩2,205.00
Beta0
1 Month Change-4.62%
3 Month Change-8.83%
1 Year Change-25.86%
3 Year Change-50.67%
5 Year Changen/a
Change since IPO-56.64%

Recent News & Updates

Recent updates

Shareholder Returns

A322970KR BiotechsKR Market
7D4.5%4.0%3.2%
1Y-25.9%22.1%13.4%

Return vs Industry: A322970 underperformed the KR Biotechs industry which returned 22.1% over the past year.

Return vs Market: A322970 underperformed the KR Market which returned 13.4% over the past year.

Price Volatility

Is A322970's price volatile compared to industry and market?
A322970 volatility
A322970 Average Weekly Movement12.0%
Biotechs Industry Average Movement8.0%
Market Average Movement5.2%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A322970 has not had significant price volatility in the past 3 months.

Volatility Over Time: A322970's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/ahttps://www.moogene.com

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease.

Moogene Medi Co., Ltd. Fundamentals Summary

How do Moogene Medi's earnings and revenue compare to its market cap?
A322970 fundamental statistics
Market cap₩25.84b
Earnings (TTM)₩0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A322970 income statement (TTM)
Revenue₩0
Cost of Revenue₩0
Gross Profit₩0
Other Expenses₩0
Earnings₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A322970 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.